Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin on Atherosclerosis, β-Cell Function, and Glycemic Control in Japanese Patients with Type 2 Diabetes Mellitus Who are Treatment Naïve or Poorly Responsive to Antidiabetes Agents: A Multicenter, Prospective Observational, Uncontrolled Study

• Main Authors: Yuya Tsurutani, MD, PhD (Author), Masao Omura, MD, PhD (Author), Yoko Matsuzawa, MD, PhD (Author), Jun Saito, MD, PhD (Author), Mariko Higa, MD, PhD (Author), Matsuo Taniyama, MD, PhD (Author), Tetsuo Nishikawa, MD, PhD (Author)
• Format: Book
• Published: Elsevier, 2017-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Sitagliptin, a dipeptidyl peptidase-4 inhibitor, is widely used in patients with type 2 diabetes. However, the pleiotropic effects of sitagliptin is not well understood. Objective: To assess the clinical efficacy and safety of sitagliptin on atherosclerosis, β-cell function, and glycemic...